Drug news

FDA approves Binosto (EffRx) for Osteoporosis

Read time: 1 mins

Last updated:16th Mar 2012

Published:16th Mar 2012

Source: Pharmawand

The FDA has approved Binosto (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of Osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with Osteoporosis. EffRx anticipates that Binosto will be commercially available in the United States in the third quarter of 2012. Binosto was developed by EffRx based on an agreement with Merck & Co granting EffRx the worldwide rights to all effervescent and related patents of Fosamax (alendronate). Patents have been granted to EffRx providing exclusivity for Binosto through February 2023. Additional patents are pending.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves Biktarvy label update with data for pregnant adults with HIV

Gilead Sciences, Inc. announced the FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads

1 mins

Drug news

Positive overall survival results of Anktiva combined with checkpoint inhibitors in non-small cell lung cancer; meeting scheduled with FDA to discuss registration path for Anktiva in lung cancer

ImmunityBio, Inc., an immunotherapy company, announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab) and standard-of-care chemotherapy

2 min

Drug news

MHRA approves Yorvipath (palopegteriparatide) to treat chronic hypoparathyroidism

Ascendis Pharma has announced that its drug Yorvipath has been approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA) for the treatment of chronic hypoparathyroidism in adults – A condition that causes cramps and spasms due to low levels of calcium and PTH

1 min

See all news